Literature DB >> 8190721

Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells.

K Sato1, J Ishizuka, C W Cooper, D H Chung, T Tsuchiya, T Uchida, S Rajaraman, C M Townsend, J C Thompson.   

Abstract

Calcium, which binds to calmodulin inside the cells, is an important mediator of various intracellular processes, including cell proliferation. We speculated that blockade of Ca2+ influx into the cells by Ca(2+)-channel blockers, such as phenytoin and verapamil, might affect the Ca(2+)-calmodulin pathway leading to suppression of cell growth. In this study, we examined the effect of phenytoin and verapamil on growth of two human pancreatic cancer cell lines, MIA PaCa-2 and CAV, in vitro and in vivo. Both phenytoin and verapamil inhibited growth of the two cell lines in a dose-dependent fashion. Phenytoin and verapamil each significantly prolonged doubling time of MIA PaCa-2 and the combination of the two drugs acted synergistically. The activity of ornithine decarboxylase, which is a rate-limiting enzyme of the polyamine pathway that is closely related to cell proliferation, was significantly inhibited by both drugs in a time-dependent fashion. Phenytoin, but not verapamil, inhibited growth of MIA PaCa-2 tumors xenotransplanted into nude mice, whereas both phenytoin and verapamil inhibited the growth of CAV tumors. Since phenytoin and verapamil are known to have fewer side effects than conventional antineoplastic drugs, these results suggest their possible use in novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190721     DOI: 10.1097/00006676-199403000-00009

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

Review 1.  Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges.

Authors:  Alina L Capatina; Dimitris Lagos; William J Brackenbury
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

Review 2.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

3.  Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.

Authors:  Samuel J Tingle; John A Moir; Steven A White
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 4.  Cav1.2, cell proliferation, and new target in atherosclerosis.

Authors:  Nikolai M Soldatov
Journal:  ISRN Biochem       Date:  2013-05-12

Review 5.  Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

Authors:  Tomas Koltai
Journal:  F1000Res       Date:  2015-07-22

Review 6.  Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma.

Authors:  Julie Schnipper; Isabelle Dhennin-Duthille; Ahmed Ahidouch; Halima Ouadid-Ahidouch
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

7.  Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.

Authors:  Neha Woods; Jose Trevino; Domenico Coppola; Srikumar Chellappan; Shengyu Yang; Jaya Padmanabhan
Journal:  Oncotarget       Date:  2015-11-03

8.  Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women's Health Initiative Study.

Authors:  Zhensheng Wang; Donna L White; Ron Hoogeveen; Liang Chen; Eric A Whitsel; Peter A Richardson; Salim S Virani; Jose M Garcia; Hashem B El-Serag; Li Jiao
Journal:  J Clin Med       Date:  2018-08-02       Impact factor: 4.241

9.  Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth.

Authors:  Husain Yar Khan; Gabriel B Mpilla; Rachel Sexton; Srikant Viswanadha; Kumar V Penmetsa; Amro Aboukameel; Maria Diab; Mandana Kamgar; Mohammed Najeeb Al-Hallak; Mark Szlaczky; Anteneh Tesfaye; Steve Kim; Philip A Philip; Ramzi M Mohammad; Asfar S Azmi
Journal:  Cancers (Basel)       Date:  2020-03-22       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.